Erratum: Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis (The AAPS Journal DOI: 10.1208/s12248-010-9249-2);Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis

AAPS Journal

Volumn 13, Issue 1, 2011, Pages 72-82

  Valenzuela, Belén ^a   Nalda Molina, Ricardo ^b   Bretcha Boix, Pere ^a   Escudero Ortíz, Vanesa ^a   Duart, Maria José ^b   Carbonell, Vicente ^c   Sureda, Manuel ^a   Rebollo, José Pascual ^a   Farré, Josep ^a   Brugarolas, Antonio ^a   Pérez Ruixo, Juan José ^b  

^a USP Hospital San Jaime   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c Centro Tecnologico Ainia   (Spain)

Author keywords

Hyperthermic intraperitoneal chemotherapy (HIPEC); NONMEM; Oxaliplatin; Peritoneal carcinomatosis; Pharmacodynamics; Pharmacokinetics

Indexed keywords

FLUOROURACIL; OXALIPLATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PERITONEAL FLUID LEVEL; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTHERMIC THERAPY; INCIDENCE; LAPAROTOMY; LYMPHADENECTOMY; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; NEUTROPHIL COUNT; PERITONEUM CANCER; PREDICTION; STEM CELL; TIME;

EID: 79951999537     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9262-0     Document Type: Erratum

References (50)

1. Koga A, Watanabe K, Fukuyama T, et al. Diagnosis and operative indications for polypoid lesions of the gallbladder. Ann Surg. 1988;123:26-9. (Pubitemid 18059402)
2. Fujimoto S, Shrestha RD, Kokubun M, et al. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann Surg. 1990;212: 592-6.
3. Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg. 1994;18:150-5. (Pubitemid 24100707)
4. Alexander HR, Hanna N, Pingpank JF. Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma. Cancer Treat Res. 2007;134:343-55.
5. Witkamp AJ, de Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer. 2001;37:979-84. (Pubitemid 32397682)
6. Lentz SS, Miller BE, Kucera GL, Levine EA. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma. Gynecol Oncol. 2007;106:207-10. (Pubitemid 46898595)
7. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14:254-61. (Pubitemid 28146518)
8. Los G, Mutsaers PH, van der Vijgh WJ, et al. Direct diffusion of cisplatinum in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989;48:3380-4. (Pubitemid 19162154)
9. Elias D, Ouellet JF. Intraperitoneal chemohyperthermia. Rationale, technique, indications and results. Surg Oncol Clin N Am. 2001;10:915-33.
10. Verwaal V, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-43. (Pubitemid 46606227)
11. Verwaal V, van Ruth S, Witkamp A, et al. Long term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65-71. (Pubitemid 40486643)
12. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89:480-7. (Pubitemid 27147264)
13. Cho HK, Lush RM, Bartlett DL, et al. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion to patients with peritoneal carcinomatosis. J Clin Pharmacol. 1999;39:1-8.
14. Fujimoto S, Takahashi M, Mutou T, et al. Survival time and prevention of side effects of intraperitoneal hyperthermic perfusion with mitomycin C combined with surgery for patients with advanced gastric cancer. Cancer Treat Res. 1996;81:169-76.
15. Steller MA, Egorin MJ, Trimble EL, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol. 1999;43:106-14. (Pubitemid 29045027)
16. de Bree E, Rosing H, Filis D, et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol. 2008;15:1183-92.
17. Elias D, Goere D, Blot F, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14:1818-24. (Pubitemid 46870938)
18. Elias D, Pocard M, Goere D. HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin. Cancer Treat Res. 2007;134:303-18.
19. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681-5.
20. Urano M, Ling CC. Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro. Int JHyperthermia. 2002;18:307-15. (Pubitemid 34700198)
21. Atallah D, Marsaud V, Radanyi C, et al. Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines. Int J Hyperthermia. 2004;20:405-19. (Pubitemid 38832570)
22. Elias D, Bonnay M, Puizillou JM, et al. Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267-72. (Pubitemid 34704979)
23. Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastasic colorectal cancer and its potential in other malignancies. Drugs. 2000;60:895-924.
24. Elias D, Sideris L. Pharmacokinetics of heated introperative intreperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am. 2003;12:755-69. (Pubitemid 36920097)
25. Elias D, Raynard B, Bonnay M, Pocard M. Heated intraoperative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studies. Eur J Surg Oncol. 2006;32:607-13. (Pubitemid 44063994)
26. Stewart JH, Shen P, Russell G, et al. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol. 2008;15:2137-45.
27. Ferron G, Dattez S, Gladieff L, et al. Pharmacokinetics of heated intraperitoneal oxaliplatin. Cancer Chemother Pharmacol. 2008;62:679-83.
28. Mahteme H, Wallin I, Glimelius B, et al. Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneasl perfusion. Eur J Clin Pharmacol. 2008;64:907-11.
29. Mohamed F, Sugarbaker PH. Carrier solutions for intraperitoneal chemotherapy. Surg Oncol Clin N Am. 2003;12:813-24. (Pubitemid 36920101)
30. Friberg LE, Henningsson A, Maas H, et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20:4713-21. (Pubitemid 36025290)
31. Bretcha-Boix P, Farré-Alegre J, Sureda M, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies. Clin Transl Oncol. 2010;12:437-42.
32. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Sem Surg Oncol. 1998;14:254-61. (Pubitemid 28146518)
33. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29-42.
34. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-74.
35. Sugarbaker PH, Jacquet P, Stephens AD, et al. Comparison of covered versus closed technique for heated intraoperative intraperitoneal chemotherapy for peritoneal carcinomatosis from gastrointestinal cancer. In: Abe O, Inokuchi K, Takasaki K, editors. Monduzzi Editore. Bologna: XXX World Congress of the International College of Surgeons; 1996. p. 389-93.
36. Giachetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomoduled fluorouracil-leucovorin as first line treatment of metastasic colorectal cancer. J Clin Oncol. 2000;18:136-47. (Pubitemid 30036347)
37. Beal SL, Sheiner LB, Boeckman AJ (ed) NONMEM users guides. ICON Development Solutions, Ellicott City, 1989-2006.
38. Sandström M, Lindman H, Nygren P, et al. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin- cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol. 2006;58:143-56.
39. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17-20. (Pubitemid 46944205)
40. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman & Hall/CRC; 1993.
41. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28:171-92.
42. Massari C, Brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol. 2000;45:157-64. (Pubitemid 30090247)
43. Schmitt A, Gladieff L, Laffont CM, et al. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol. 2010;28:4568-74.
44. Léger F, Loos WJ, Bugat R, et al. Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther. 2004;76:567-78. (Pubitemid 39601546)
45. Latz JE, Karlsson MO, Rusthoven JJ, et al. A semimechanisticphysiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol. 2006;57:412-26. (Pubitemid 43087584)
46. Sandström M, Lindman H, Nygren P, et al. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol. 2005;23:413-21. (Pubitemid 46224216)
47. Trocóniz IF, Garrido MJ, Segura C, et al. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumors. Cancer Chemother Pharmacol. 2006;57:727-35.
48. Kathman SJ, Williams DH, Hodge JP, et al. A Bayesian population PK-PD model of ispinesib-induced myelosuppression. Clin Pharmacol Ther. 2007;81:88-94. (Pubitemid 46050871)
49. Hing J, Perez Ruixo JJ, Stuyckens K, et al. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia. Clin Pharmacol Ther. 2008;83:130-43.
50. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer. 2006;42:2433-53. (Pubitemid 44442936)